Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | STK17B | O94768 | 1/20 | 0.45 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475728 | 1.00 | BRD4 (0.47) | BRD4CA12CA1CA2CA9 | |
| SCHEMBL30503514 | 1.00 | BRD4 (0.47) | BRD4CA12CA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL8140313 | 0.99 | BRD4 (0.46) | BRD4CA12CA1CA2CA9 | |
| SCHEMBL1232778 | 0.98 | STK17B (0.47) | BRD4CA12CA1CA2CA9 | |
| SCHEMBL1232910 | 0.93 | BCHE (0.52) | BRD4CA12CA1CA2CA9 | |
| SCHEMBL1039304 | 0.89 | MEN1 (0.44) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL12757192 | 0.88 | MEN1 (0.48) | BRD4MEN1NPC1GAARAB9A | |
| SCHEMBL3352911 | 0.85 | KDM4E (0.46) | BRD4CA12CA1CA2CA9 | |
| SCHEMBL204017 | 0.85 | MEN1 (0.48) | MEN1NPC1GAARAB9AKMT2A | |
| SCHEMBL29136642 | 0.85 | HDAC1 (0.48) | BRD4CA1CA2MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | AMBRX, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20230372511-A1 | ANTIBODY-IMMUNE AGONIST CONJUGATE AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230372511-A1 | ANTIBODY-IMMUNE AGONIST CONJUGATE AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-11717576-B2 | Antibody-immune agonist conjugate and applications thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-11717576-B2 | Antibody-immune agonist conjugate and applications thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-08-08 | — | — | US | disclosed |
| CN-116457023-A | antibody-TLR agonist conjugates, methods and uses thereof | AMBRX公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-4199968-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | Ambrx, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-1198233-A4 | SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1198233-A1 | SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2002-04-24 | — | — | EP | disclosed |
| EP-1198232-A1 | UREA SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2002-04-24 | — | — | EP | disclosed |
| US-6376669-B1 | COMPLEXES | 3M INNOVATIVE PROPERTIES COMPANY | 2002-04-23 | — | — | US | disclosed |
| US-6331539-B1 | INDUCE BIOSYNTHESIS OF INTERFERON ALPHA IN ANIMALS | 3M INNOVATIVE PROPERTIES COMPANY | 2001-12-18 | — | — | US | disclosed |
| WO-2001034709-A1 | DYE LABELED IMIDAZOQUINOLINE COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2000076518-A1 | UREA SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000076519-A1 | SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| US-6069149-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | TERUMO KABUSHIKI KAISHA (JP) | 2000-05-30 | — | — | US | disclosed |
| EP-0894797-A1 | NOVEL AMIDE DERIVATIVES AND INTERMEDIATES FOR THE SYNTHESIS THEREOF | TERUMO KABUSHIKI KAISHA (JP) | 1999-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372511-A1 | ANTIBODY-IMMUNE AGONIST CONJUGATE AND APPLICATIONS THEREOF | FCGR1A, FCGR2A, TLR3 | BRD4 3529/4885CA12 932/4885CA1 2530/4885 |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | BRD4 1406/4885CA12 3178/4885CA1 4735/4885 |
| US-11717576-B2 | Antibody-immune agonist conjugate and applications thereof | FCGR1A, FCGR2A, TLR3 | BRD4 3529/4885CA12 932/4885CA1 2530/4885 |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | TLR3, TLR2, TLR1 | BRD4 1079/4885CA12 2287/4885CA1 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.